McDermott Advises Therapeutic AI Pioneers Diabeloop SA on Joint Development Agreement with Terumo Medical Corporation - McDermott Will & Emery

McDermott Advises Therapeutic AI Pioneers Diabeloop SA on Joint Development Agreement with Terumo Medical Corporation

Overview


The French company Diabeloop SA, a pioneer in therapeutic AI, and Terumo Corporation, a global leader in medical technology, announced today that they have signed an agreement for the joint development with exclusive distribution rights in Japan of an automated insulin delivery (AID) solution. The Diabeloop-developed system will integrate Terumo’s innovative insulin patch pump.

McDermott Will & Emery advised Diabeloop SA with Fabrice Piollet, Emmanuelle Trombe, Anne-France Moreau, Mathilde Peschard and Edouard Becker.

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts